delanzomib
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2007 (NCT00572637)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Proteasome subunit beta type-10INHIBITOR
PSMB10 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H](NC(=O)[C@@H](NC(=O)c1cccc(-c2ccccc2)n1)[C@@H](C)O)B(O)O- Mol. weight
- 413.28 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL270515 ↗
Also known as
- cep-18770
- cep-18770
- cep-18770
- delanzomib
- delanzomib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01348919 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2011 | Cephalon |
| NCT01023880 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2010 | Cephalon |
| NCT00572637 | Phase 1 | Nov 1, 2007 | Ethical Oncology Science, Ospedale S. Giovanni Bellinzona |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cephalon | For profit | 2 | 2 | 1 | 2010 |
| Ethical Oncology Science | For profit | 1 | 1 | 1 | 2007 |
| Ospedale S. Giovanni Bellinzona | Academic/Hospital | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1